File Download
Supplementary

Conference Paper: Bortezomib combines with suberoylanilide hydroxamic acid (SAHA) to synergistically induce caspase-dependent apoptosis and blocks SAHA's activation of EBV lytic cycle in nasopharyngeal carcinoma

TitleBortezomib combines with suberoylanilide hydroxamic acid (SAHA) to synergistically induce caspase-dependent apoptosis and blocks SAHA's activation of EBV lytic cycle in nasopharyngeal carcinoma
Authors
Issue Date2012
PublisherICOHAD 2012.
Citation
The 2012 International Congress on Oncogenic Herpesviruses and Associated Diseases (ICOHAD 2012), Philadelphia, PA., 1-4 August 2012. In Conference Program, 2012, p. 36, abstract no. 3.13 How to Cite?
AbstractHistone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), could induce Epstein-Barr virus (EBV) lytic cycle and apoptosis in EBV-positive nasopharyngeal carcinoma (NPC) cells. In this study, we investigated the effects of combining a proteasome inhibitor, bortezomib, with SAHA in the treatment of NPC cells. Synergistic killing of a panel of EBV-positive NPC cells upon treatment with various combinations of bortezomib (0, 7.5, 15, 30, 60 and 120 nM) and SAHA (0, 0.625, 1.25, 2.5, 5 and 10 uM) was demonstrated by MTT assay and isobologram analysis. The synergistic killing was due to apoptosis as demonstrated by markedly increased sub-G1, annexin V-positive and TUNEL-positive cell populations. Strong proteolytic cleavage of PARP, caspase-3, -7 and -9 and increased reactive oxygen species …
DescriptionPoster Session 1 - Vaccines and Anti-Viral Therapeutics: no. 3.13
Persistent Identifierhttp://hdl.handle.net/10722/165604

 

DC FieldValueLanguage
dc.contributor.authorHui, KFen_US
dc.contributor.authorLam, BHWen_US
dc.contributor.authorHo, DNYen_US
dc.contributor.authorChiang, AKSen_US
dc.date.accessioned2012-09-20T08:21:00Z-
dc.date.available2012-09-20T08:21:00Z-
dc.date.issued2012en_US
dc.identifier.citationThe 2012 International Congress on Oncogenic Herpesviruses and Associated Diseases (ICOHAD 2012), Philadelphia, PA., 1-4 August 2012. In Conference Program, 2012, p. 36, abstract no. 3.13en_US
dc.identifier.urihttp://hdl.handle.net/10722/165604-
dc.descriptionPoster Session 1 - Vaccines and Anti-Viral Therapeutics: no. 3.13-
dc.description.abstractHistone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), could induce Epstein-Barr virus (EBV) lytic cycle and apoptosis in EBV-positive nasopharyngeal carcinoma (NPC) cells. In this study, we investigated the effects of combining a proteasome inhibitor, bortezomib, with SAHA in the treatment of NPC cells. Synergistic killing of a panel of EBV-positive NPC cells upon treatment with various combinations of bortezomib (0, 7.5, 15, 30, 60 and 120 nM) and SAHA (0, 0.625, 1.25, 2.5, 5 and 10 uM) was demonstrated by MTT assay and isobologram analysis. The synergistic killing was due to apoptosis as demonstrated by markedly increased sub-G1, annexin V-positive and TUNEL-positive cell populations. Strong proteolytic cleavage of PARP, caspase-3, -7 and -9 and increased reactive oxygen species …-
dc.languageengen_US
dc.publisherICOHAD 2012.-
dc.relation.ispartofInternational Congress on Oncogenic Herpesviruses and Associated Diseases, ICOHAD 2012en_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleBortezomib combines with suberoylanilide hydroxamic acid (SAHA) to synergistically induce caspase-dependent apoptosis and blocks SAHA's activation of EBV lytic cycle in nasopharyngeal carcinomaen_US
dc.typeConference_Paperen_US
dc.identifier.emailHui, KF: kfhui@hku.hken_US
dc.identifier.emailHo, DNY: hodona@hku.hken_US
dc.identifier.emailChiang, AKS: chiangak@hku.hken_US
dc.identifier.authorityChiang, AKS=rp00403en_US
dc.description.naturepostprint-
dc.identifier.hkuros209512en_US
dc.identifier.spage36, abstract no. 3.13-
dc.identifier.epage36, abstract no. 3.13-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats